

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A substance for preventing, delaying the onset of or treating ~~one or more than one autoimmune disease~~ type I diabetes, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding ~~one or more than one autoantigen for the autoimmune disease~~ secreted glutamic acid decarboxylase (secreted GAD).

2. (currently amended) A method of making a medicament comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding ~~one or more than one autoantigen for an autoimmune disease~~ secreted glutamic acid decarboxylase (secreted GAD) for the manufacture of a medicament for preventing, delaying the onset of or treating ~~the one or more than one autoimmune disease~~ type I diabetes, the method comprising providing a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding ~~one or more than one autoantigen for the autoimmune disease~~ secreted glutamic acid decarboxylase (secreted GAD).

3. (canceled)

4. (canceled)

5. (previously presented) The method according to claim 2, where the medicament is manufactured in dosage units of between about 0.5 mg to about 5 mg.

6. (previously presented) The method according to claim 2, where the medicament is manufactured in dosage units of between about 1 mg to about 4 mg.

7. (previously presented) The method according to claim 2, where the medicament is manufactured in dosage units of between about 2.5 mg to about 3 mg.

8. (previously presented) The method according to claim 2, where the medicament is manufactured in a form suitable for intramuscular administration.

9. (previously presented) The method according to claim 2, where the medicament is manufactured in a form suitable for intravenous administration.

10. (currently amended) A method for preventing, delaying the onset of or treating an autoimmune disease type I diabetes in a patient comprising:

a) selecting a patient who is susceptible to developing the autoimmune disease type I diabetes, who is developing the autoimmune disease type I diabetes or who has the autoimmune disease type I diabetes; and

b) administering to the patient one or more than one dose of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding ~~one or more than one autoantigen for the autoimmune disease~~ secreted glutamic acid decarboxylase (secreted GAD).

11. (canceled)

12. (currently amended) The method of claim ~~11~~ 10, where selecting the patient comprises identifying in the patient the presence of anti-insulin or anti-GAD autoantibodies or both anti-insulin and anti-GAD autoantibodies.

13. (currently amended) The method of claim ~~11~~ 10, where selecting the patient comprises identifying in the patient the presence of increasing hyperglycemia.

14. (currently amended) The method of claim ~~11~~ 10, where selecting the patient comprises identifying in the patient the presence of glycosuria.

15. (currently amended) The method of claim 10, where selecting the patient comprises identifying in the patient the presence of a genetic predisposition ~~to the autoimmune disease~~ type I diabetes.

16. (original) The method of claim 10, where the one or more than one dose is a plurality of doses.

17. (original) The method of claim 10, where administering to the patient one or more than one dose comprises injecting the patient intramuscularly with the one or more than one dose.

18. (currently amended) The method of claim 10, further comprising, after administering, monitoring the patient for the development ~~the autoimmune disease~~ type I diabetes.

19-24. (canceled)